Navigation Links
Charles C. Harwood, Jr., Joins Cellectar, Inc.'s Board of Directors
Date:9/18/2008

MADISON, Wis., Sept. 18 /PRNewswire/ -- Cellectar, Inc., a privately-held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, today announced the appointment of Charles C. Harwood, Jr., to the Company's Board of Directors.

Mr. Harwood, 55, is a Healthcare Industry Advisor for Avista Capital Partners, a NYC-based private equity firm. Prior to working with Avista, Mr. Harwood was President and Chief Executive Officer of privately-held Focus Diagnostics, Inc. from 2002 until the company's sale in 2006. With more than 20 years of experience in the healthcare industry, he has also served as Senior Vice President and Chief Financial Officer of Covance, Inc., one of world's largest drug development service companies.

"Charlie brings exceptional financial and transaction expertise to the Cellectar Board," commented William Clarke, MD, M.Sc, President and CEO of Cellectar. "His years of experience in the drug development industry will prove beneficial to the Company as we advance our radiopharmaceutical products toward clinical testing and commercialization."

Mr. Harwood also serves on the Board of Directors at BioReliance, Inc., a contract research organization specializing in biological safety testing and specialized toxicology, RadPharm, Inc., a privately-held contract research organization located in Princeton, NJ, and Itero Biopharmaceuticals, Inc., a development stage company located in the San Francisco Bay Area.

About Cellectar

Cellectar, Inc. is a radiopharmaceutical company that designs, develops and manufactures products to detect, treat and monitor a wide variety of human cancers. Cellectar's novel product candidates combine lipid-like molecules, phospholipid ethers (PLEs) analogs, with radioisotopes that can either image or destroy malignant cells. Cellectar's products' unique mechanism of action is based on their accumulation and selective retention in malignant tumors and not in normal cells. The Company's operations are based in Madison, WI. Cellectar has previously raised approximately $22.0 million from angel and venture capital investors; including Continuum Investment Partners and Venture Investors, LLC. For further information about Cellectar, visit the Company's website at http://www.cellectar.com.


'/>"/>
SOURCE Cellectar, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at The Association for Research in Vision and Ophthalmology
2. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
3. Dr. Charles A. Sims of California Cryobanks Family Cord Blood Services Named to National Stem Cell Advisory Council
4. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
5. Informed Medical Communications Appoints Charles T. Saldarini to Board of Directors
6. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
7. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
8. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
9. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
10. GM Exec Joins Bio-Reaction Industries Board of Directors
11. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Shimadzu Scientific Instruments (SSI) will ... Marijuana Business Conference and Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis ... attendees can stop by booth 1021 to learn how Shimadzu’s instruments can help ...
(Date:4/27/2016)... York, NY (PRWEB) , ... April 27, 2016 ... ... realizing it. Touch screen mobile devices with fingerprint recognition for secure access, ... libraries are only a few ways consumers are interacting with biometrics technology today. ...
(Date:4/27/2016)... RESEARCH TRIANGLE PARK, N.C. , April 27, ... ) announced today that Martine Rothblatt , Ph.D., ... provide an overview and update on the company,s business ... Care Conference. The presentation will take place ... Time, and can be accessed via a live webcast ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... that Jon Clark has joined the company as an Expert Consultant. Mr. ... for industry collaborations and managing the development of small molecule monographs based on ...
Breaking Biology Technology:
(Date:3/15/2016)... March 15, 2016 --> ... by Transparency Market Research "Digital Door Lock Systems Market - ... - 2023," the global digital door lock systems market in ... 2014 and is forecast to grow at a CAGR of ... small and medium enterprises (MSMEs) across the world and high ...
(Date:3/14/2016)... -- NXTD ) ("NXT-ID" or the "Company"), a ... airing of a new series of commercials on Time Warner ... st .  The commercials will air on Bloomberg TV, Fox ... Street show. --> NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ...
(Date:3/11/2016)... HANOVER, Germany , March 11, 2016 ... - Cross reference: Picture is available at AP Images ( ... scanner from DERMALOG will be used to produce the new refugee ... of other biometric innovations, at CeBIT in Hanover ... LF10 scanner from DERMALOG will be used to produce the new ...
Breaking Biology News(10 mins):